Antimalarial pyrido[1,2-a]benzimidazoles.

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Antimalarial drug resistance necessitates the development of novel therapeutic agents.
• Pyrido[1,2-a]benzimidazoles represent a novel chemical class with potential antimalarial properties.

Purpose of the Study:

• To synthesize and evaluate a novel class of pyrido[1,2-a]benzimidazoles for antiplasmodial activity and cytotoxicity.
• To identify lead compounds with improved efficacy against drug-resistant Plasmodium falciparum strains.

Main Methods:

• Synthesis of pyrido[1,2-a]benzimidazole derivatives.
• In vitro evaluation of antiplasmodial activity against various Plasmodium falciparum strains, including drug-resistant K1.
• Cytotoxicity assessment using the L-6 mammalian cell line.
• In vivo efficacy studies in Plasmodium berghei infected mice.

Main Results:

• The compound TDR86919 (4c) exhibited potent in vitro activity against Plasmodium falciparum (IC(50) = 0.047 μM), outperforming chloroquine against the K1 strain.
• Compound 4c demonstrated high selectivity with a selectivity index of >600 against the L-6 cell line.
• Significant in vivo efficacy was observed in mice, with >90% parasitemia inhibition and increased mean survival time following oral and intraperitoneal administration.
• Metabolic stability of the alkylamino side chain was identified as a factor influencing in vivo activity.

Conclusions:

• Pyrido[1,2-a]benzimidazoles are a promising class of novel antimalarial compounds with potent activity against drug-resistant malaria parasites.
• Compound 4c and its analogues show excellent in vitro and in vivo efficacy with low cytotoxicity, warranting further investigation.
• Optimization of metabolic stability is crucial for enhancing the in vivo performance of these compounds as antimalarial agents.